Physician profile
Oleksandr Stupnytskyi
NPI 1598712739
$4,909.54
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $194 · 2022: $899 · 2023: $1,373 · 2024: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $800.66 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $545.29 | 2019-2024 | |
| Novo Nordisk INC | $461.27 | 2019-2024 | Rybelsus, Ozempic, Saxenda |
| Abbvie INC. | $421.39 | 2019-2024 | Qulipta, Linzess, Viberzi |
| Amgen INC. | $250.81 | 2019-2024 | Repatha, Evenity, Prolia |
| Sumitomo Pharma America, INC. | $207.75 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $206.70 | 2019-2024 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $196.51 | 2019-2024 | Eliquis |
| Lilly USA, LLC | $193.42 | 2019-2024 | Jardiance, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.16 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $174.08 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $150.05 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.42 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $99.89 | 2023-2024 | Veozah |
| Merck Sharp & Dohme LLC | $87.28 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleksandr Stupnytskyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.